Man Group’s Pyxis Oncology PYXS Stock Holding History

Man Group’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-52,954	Closed	-$175K	–	2161
2024 Q2	$175K	Sell	52,954 -94,226	-64%	-$396K	﹤0.01%	1910
2024 Q1	$627K	Buy	+147,180	New	+$619K	﹤0.01%	1712

Other funds holding PYXS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Man Group's PYXS Position: Q3 2024 in Review

Man Group sold out of Pyxis Oncology (PYXS) in Q3 2024, closing a stake of 52,954 shares — an estimated $175K sold.

Man Group first reported a position in PYXS in Q1 2024 and held it in 2 quarters. The position peaked at $627K in Q1 2024. 92 funds tracked by Wall St. Rank hold PYXS as of Q3 2024.

Man Group reported no remaining Pyxis Oncology position as of Q3 2024 after selling out during the quarter.
Man Group sold 52,954 Pyxis Oncology shares in Q3 2024, an estimated $175K.
Man Group first reported a position in Pyxis Oncology in Q1 2024 and held it in 2 quarters.
Man Group's Pyxis Oncology position peaked at $627K in Q1 2024.
92 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.